Navigation Links
NextDocs and Novella to Present on eTMF at DIA 2013
Date:6/19/2013

CONSHOHOCKEN, Pa., June 19, 2013 /PRNewswire/ -- NextDocs announced today that it will co-present with Novella, a full service clinical research organization, at DIA 2013, the Drug Information Association annual meeting and conference.  The companies will present case studies that explore best practices for making the transition from paper trial master file to electronic trial master file (eTMF) systems.

Sharon Ames, enterprise program director at NextDocs will present alongside Krystyna Kowalczyk, executive vice president of clinical operations at Novella, in a session entitled, "That Awkward Stage: Transitioning from Paper Trial Master File to eTMF."  The session will examine how to structure a paper-to-electronic transition that incorporates the needs of ongoing studies while also meeting regulatory needs and reducing operational impacts. 

DIA 2013, the 49th annual meeting and conference of the DIA, is the largest multidisciplinary event for the pharmaceutical and life sciences industry, focusing on advancing therapeutic innovation and regulatory science.  The DIA 2013 conference takes place at the Convention and Exhibition Center in Boston from June 23 - 27, 2013. 

NextDocs and Novella's session, "That Awkward Stage: Transitioning from Paper Trial Master File to eTMF," will take place on Monday, June 24, 2013 at 2:30 p.m.  Additionally, NextDocs will be demonstrating its solutions at the DIA conference in booth #1722.

For more information on DIA 2013, visit www.diahome.org.   For more information on NextDocs, visit www.nextdocs.com.

CONTACT:
Dan Cahill
1-917-617-0106
dcahill@roaringpr.com


'/>"/>
SOURCE NextDocs
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NextDocs Expands Customer Roster by More Than 10 Percent
2. NextDocs Launches QuickStart for Emerging Growth Companies
3. NextDocs 6: The New Enterprise Standard for Regulated Content Management
4. NextDocs Corporation Announces Trial Exchange, a Clinical Portal Designed Specifically for Clinical Trial Sites and Integrated with eTMF
5. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
6. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
7. Pharma IQ Presents the Latest Trends in Clinical Trial Supply
8. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
9. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
10. Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House
11. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 20, 2017 ResMed (NYSE: RMD ), BMC ... Winter Haven, Florida ) today announced they have agreed on ... 3B will be permitted to sell their existing products in exchange ... settlement payment to 3B to close the Florida ... an admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... 20, 2017  Today, during a plenary ... Pathways in Immunology, Growth Disorders and Cancer," ... INFI ) presented preclinical data for ... selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Preclinical data showed ... resistance to checkpoint inhibition by remodeling the ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver Panel, Renal ... report to their offering. ... The global clinical laboratory testing market is expected ... innovative solutions on the grounds of maximum efficiency and minimum error ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company ... with school-aged children since the holiday season. , “It happens every year around ... sharing hugs and taking photos, which is the head-to-head gateway that lice need to ...
(Date:1/20/2017)... ... ... International Protein, a company based out of Australia that focuses on developing ... trade show in Hilton Head, SC. , International Protein was founded by Christine ... of products that would elevate her fitness regime. At this ECRM trade show, Envall ...
(Date:1/20/2017)... California (PRWEB) , ... January 20, 2017 , ... "TransFlare ... to use inside of Final Cut Pro X," said Christina Austin - CEO of ... the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Mary Magdalene: Grace ... mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is ... who spent her career as an educator interacting with countless women who had little ...
(Date:1/20/2017)... ... ... account following a man who went on to support his country and serve the Lord. ... Haven, Florida and at the age of 5, his family moved to Pensacola Florida. In ... and got married right out of boot camp. , He and his wife raised ...
Breaking Medicine News(10 mins):